EASL | The Home of Hepatology’s Post

The 4th International Symposium on Interstitial Lung Disease (ILD) in Rheumatic Diseases will convene virtually on January 12-14. Intended for scientists and clinicians who focus on rheumatic diseases like #scleroderma, this meeting aims to draw attention to #ILD and share recent progress by the world's top researchers and clinicians. We're pleased to share that CONQUEST, the SRF-driven platform clinical trial, will be featured in this event. The goal of CONQUEST is to rapidly evaluate potential treatments for scleroderma-associated ILD. Dr. Dinesh Khanna of the University of Michigan (pictured right) and Dr. Toby Maher of Keck School of Medicine (pictured left), the co-chairs of the CONQUEST steering committee, will share a presentation that discusses this groundbreaking clinical trial. Through CONQUEST, the SRF is spurring vital therapeutic innovation. In short, it's a game-changer. We are so grateful for the opportunity to share this work with the greater scientific and medical community—collaboration is essential to making progress. ➡️ Learn more & register for the symposium: https://lnkd.in/gAhFadTn ➡️ Learn more about CONQUEST: https://lnkd.in/gex9KYwq #sclerodermaresearch #srfcure #conquest #sayscleroderma

🌟 Help us raise awareness for Pulmonary Fibrosis Month! 🌟  At NUVISAN, we have a clear mission: to fight pulmonary fibrosis. And how? Through state-of-the-art fibrosis modeling and precision cut lung slices.  Lung health is crucial, and fibrosis -the excessive scarring- possess a challenge. Our experienced scientists, Danny Schnerwitzki, excel at producing reliable fibrosis models that enrich our understanding of these complicated diseases. In the realm of fibrosis, TGF-β levels fuel disease progression. Our efforts in establishing reliable 3D tissue models include treatment of fibrosis in precision cut lung slices with Nintedanib and Pirfenidone, which successfully reduces antifibrotic markers. Our results, validated by ELISA and RT-PCR, are compelling. Why not explore your treatment approach with our models? Take the chance to evaluate toxicity or therapeutic potential with us. Let's create a brighter therapeutic horizon together. Join hands with us to make a difference this Lung Fibrosis Month.  #LungFibrosisDay #FibrosisResearch #Innovation #NUVISAN #3Dmodel #PCTS #TogetherForChange

Interesting news from the NHS England GRAIL Galleri test in the UK - accuracy in the article given as 56% One of the main issues I think with Galleri is its model trained on late stage disease, and is a “fixed” panel. By comparison look at the recent results from Guardant Health and Exact Sciences where their CRC early detection assays pushed > 80% accuracy (COI - I am co-I in Guardant Health CORRECT-MRD-1) We need broader WG assays trained on early disease - we are developing a Nanopore assay with Isidro Cortés Ciriano which combines SNV, CNV, SV, Fragmentomics, Motif analysis and epigenetics (5-mC and 5-hMC) to build the best model possible. https://lnkd.in/eF8QN-q4

🌐 For the first time, #INESCTEC leads a large-scale European project (€6.9M) entirely focused on lung diseases.💡 It's called AI4Lungs —a €6.9M initiative solely dedicated to revolutionizing how we approach lung diseases. Imagine a future where AI streamlines diagnosis and treatment processes for respiratory conditions, from pneumonia to COVID-19, to cancer. AI4Lungs leverages diverse clinical data sources, making it a game-changer for physicians and facilitating the clinical processing of patients with any symptom of respiratory disease, reducing costs, and optimising the allocation of resources. 🤖💼 Here's what you need to know 👇 https://lnkd.in/d5BHpMBc Hélder P. Oliveira | Duarte Dias | i3S - Instituto de Investigação e Inovação em Saúde | #CHVNGE #AI4Lungs #HealthcareInnovation #MedicalAI #RespiratoryHealth

In a recently published review article, researchers from University Hospital Southampton NHS FT and the University of Southampton evaluate PExA's technology by summarizing results from previous studies using PExA and comparable methods. The measurement of specific biomarkers of airway inflammation obtained directly from the RTLF by PExA enables a more accurate and comprehensive understanding of pathophysiological changes at the molecular level in patients with acute and chronic lung diseases. The article describes how acute and chronic lung diseases are increasing and that PExA can provide unique non-invasive small airway-sampling.   The article titled "Particles in Exhaled Air (PExA): Clinical Uses and Future Implications" is publicly available via the PubMed link: https://lnkd.in/dCGx9GaY   Read the entire press release in the link below. https://lnkd.in/diWriNZq

Elucidating the inflammatory bowel disease where tiny has big impacts - Meet one of the Scipio bioscience’s grant awards winners! 🏅 For years, Dr. Rainer Glauben and Adrian Huck at Charité - Universitätsmedizin Berlin have been investigating a tiny, tricky, but key tissue in our guts, likely telling our immune system not to fight the food we eat. With his $30,000-worth prize covering Asteria™ scRNA-seq benchtop kits and sequencing, they can now dive further into the cellular composition of the Peyer’s Patches, decipher the role of different cell types, and hopefully figure out some of the causes of inflammatory bowel diseases such as Crohn’s disease. Read more about his research and the other winners here: https://lnkd.in/ewc_btYK #grant #singlecell #ibd

The continued urgency in addressing cancer and COVID-19 is evident in their dominance of clinical trial activity in 2023. Highlighting significant research focus, these diseases are at the forefront of the global health agenda. The analysis of the top 10 diseases driving clinical trials this year paints a comprehensive picture of current healthcare priorities and research efforts. Dive into Citeline's full report for an in-depth analysis of the diseases driving clinical research this year: https://lnkd.in/gGzP7yTK #ClinicalResearch #CancerResearch #COVID19 #MedicalInnovation

I am more than happy to announce that my new research article entitled “The Utility of Syndecan-1 Circulating Levels as a Biomarker in Patients with Previous or Active COVID-19: A Systematic Review and Meta-Analysis” just published in BMC Infectious Diseases (IF: 3.7, BIOMED CENTRAL LIMITED) Link: https://lnkd.in/e_WEvrhX In this meta-analysis, we found that circulating syndecan-1 level can be used as a biomarker of endothelial dysfunction in COVID-19, as it was increased in COVID-19 patients and was higher in more severe instances of the disease. Further larger studies are needed to confirm these findings and further enlighten the role of syndecan-1 in clinical settings. Thanks to Amirmohammad Khalaji, Amir Hossein Behnoush, Sanam Alilou, Mitra Norouzi, and professor Douglas Fraser. #syndecan1 #COVID19 #biomarker #systematicreview #metaanalysis